AMLX

Amylyx Pharmaceuticals, Inc.

Fundamental data last updated:September 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

 


Analyze AMLX on TradingView

VALUATION

P/E

-10.47

Market Cap ($M USD)

$1.18B

Forward P/E

7.32

PEG

0.03

PRICE TO SALES

0.00

PRICE TO BOOK

5.76

EV / EBITDA

-6.38

5-Year Average P/E

Free Cash Flow Yield

-10.20%

DCF Value

$2.30

Graham Number

N/A

Price to FCF

-9.81

EV to FCF

-7.95

Earnings Yield

-9.55%

FCF Yield

-10.20%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.36

Next Year EPS Growth Estimate

$1.94

Next Year Revenue Growth Estimate

$538.32M

Return on Equity (ROE)

-55.69%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.02

Piotroski F-Score

3

Altman Z-Score

29.95

Return on Invested Capital (ROIC)

-57.37%

Current Ratio

17.85

Quick Ratio

17.85

Net Debt to EBITDA

1.49

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-1.09

REVENUE PER SHARE

$0.00

Analyze AMLX on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Amylyx Pharmaceuticals, Inc. significantly. Based on the data at the time of this analysis, the stock traded well below its DCF Value, suggesting a potential undervaluation. The Forward P/E of 7.58 indicates optimism for future earnings, contrasting sharply with the current negative Earnings Yield, which highlights past struggles. However, the Altman Z-score of 31.56 suggests robust financial health, indicating low bankruptcy risk. This mix of metrics paints a complex picture of a company with potential growth but current financial challenges.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Amylyx Pharmaceuticals is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, potentially enhancing R&D efficiency. This adaptability could provide a competitive edge in developing cutting-edge treatments.

The Bull Case

For the value or GARP investor, Amylyx presents an intriguing opportunity. Despite a negative ROIC of -57.37%, the low Debt/Equity ratio of 0.02 and a Forward PEG of 0.03 suggest significant growth potential at a bargain. The Piotroski F-Score of 3 indicates some financial distress, yet the high Current Ratio of 17.85 showcases liquidity strength. These factors, combined with a consensus "Buy" rating, suggest that the market may be underestimating its future profitability and capital efficiency.

The Bear Case

The bear case for Amylyx is compelling, given its structural weaknesses. The Price/Book ratio of 5.96 is steep, especially when paired with a negative Price to FCF of -10.16, indicating poor cash flow generation. The stock's proximity to its 52-week high, with a 26.31% distance, suggests it might be technically overextended. Additionally, the negative EPS and zero gross profit margin highlight significant execution risks and operational inefficiencies.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$24.50

Institutional Ownership %

1-Year Beta

-0.10

Insider Buying % (6 Mo)

Distance to 52-Week High

30.84%

Distance to 52-Week Low

66.91%

EARNINGS SURPRISE %

-8.82%

50-DAY SMA

$15.23

200-DAY SMA

$13.65

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.